FilingSEC EDGAR8-K
SeaStar Medical Confirms Fulfillment of QUELIMMUNE Post-Approval Study Requirements
· SEC accepted
Stagecommercial
Filing content
The FDA has determined that the post-approval study requirements for QUELIMMUNE have been fulfilled, enabling hospitals to utilize the therapy without the previously required research infrastructure.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…